This trial is active, not recruiting.

Condition diabetes mellitus
Sponsor Dow University of Health Sciences
Start date January 2009
End date December 2010
Trial size 350 participants
Trial identifier NCT00698698, Tear proteins


Diabetes mellitus is becoming a global epidemic. There is a need to devise a non invasive method for detection of diabetes and its related complication. Tear proteins are easy to collect causing no harm to a patient and different studies indicate that tear proteins of diabetic patients are significantly different from non diabetic population. This difference in the composition of tear proteins become more pronounced with advancement of diabetic retinopathy.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case control
Time perspective cross-sectional
Normal age and sex matched population
Diabetic population with no retinopathy or Mild non proliferative diabetic retinopathy
Moderate non proliferative diabetic retinopathy
Severe non proliferative diabetic retinopathy
Proliferative diabetic retinopathy and advanced diabetic eye disease

Eligibility Criteria

Male or female participants from 30 years up to 90 years old.

Inclusion Criteria: - diabetic patients with type 2 diabetes - age above 30 - willing to participate Exclusion Criteria: - ocular surface disorders. - collagen vascular diseases - Limbal hyperemia - previous ocular surgery - creatinine level above 1.0 - liver diseases

Additional Information

Official title Tear Proteins and Diabetic Retinopathy
Principal investigator Dr. Jamshed Ahmed, FCPS
Description Diabetes mellitus causes a significant alteration in tear proteins. If we analyze tear proteins by means of electrophoresis, HPLC, and mass spectroscopy. We can find different type of tear proteins in different grades of diabetic retinopathy these biomarkers can help in mass screening , diagnosis and management of diabetic population.
Trial information was received from ClinicalTrials.gov and was last updated in January 2009.
Information provided to ClinicalTrials.gov by Dow University of Health Sciences.